Literature DB >> 14654303

Non-visual GRKs: are we seeing the whole picture?

Jonathon M Willets1, R A John Challiss, Stefan R Nahorski.   

Abstract

G-protein-coupled receptor kinases (GRKs) comprise a family of seven mammalian serine/threonine protein kinases that phosphorylate and regulate agonist-occupied or constitutively active G-protein-coupled receptors (GPCRs). Studies of the details and consequences of these mechanisms have focused heavily on the original beta-adrenoceptor kinase (beta-ARK) family (GRK2 and GRK3) and, in particular, on phosphorylation-dependent recruitment of adaptor proteins such as the beta-arrestins. However, recent work has indicated roles for the other, non-visual GRKs (GRK4, GRK5 and GRK6) and has revealed potential phosphorylation-independent regulation of GPCRs by GRK2 and GRK3. In this article, we review this newer information and attempt to put it into context with GRKs as physiological regulators that could be appropriate targets for future pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654303     DOI: 10.1016/j.tips.2003.10.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  40 in total

1.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

Review 2.  Mammalian olfactory receptors: pharmacology, G protein coupling and desensitization.

Authors:  Aya Kato; Kazushige Touhara
Journal:  Cell Mol Life Sci       Date:  2009-08-04       Impact factor: 9.261

Review 3.  Rich tapestry of G protein-coupled receptor signaling and regulatory mechanisms.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Mol Pharmacol       Date:  2008-05-30       Impact factor: 4.436

4.  Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium.

Authors:  Paul J Brighton; Timothy H Marczylo; Shashi Rana; Justin C Konje; Jonathon M Willets
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

5.  The GRK2 Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer Disease.

Authors:  Mark E Obrenovich; Hector H Palacios; Eldar Gasimov; Jerzy Leszek; Gjumrakch Aliev
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-03-03

6.  Carboxy-Terminal Phosphoregulation of the Long Splice Isoform of Free-Fatty Acid Receptor-4 Mediates β-Arrestin Recruitment and Signaling to ERK1/2.

Authors:  Ilya S Senatorov; Ameneh Cheshmehkani; Rebecca N Burns; Kirti Singh; Nader H Moniri
Journal:  Mol Pharmacol       Date:  2020-03-04       Impact factor: 4.436

7.  GRK3 is essential for metastatic cells and promotes prostate tumor progression.

Authors:  Wenliang Li; Nanping Ai; Suming Wang; Nandita Bhattacharya; Vladimir Vrbanac; Michael Collins; Sabina Signoretti; Yanhui Hu; Frederick M Boyce; Karsten Gravdal; Ole J Halvorsen; Hawa Nalwoga; Lars A Akslen; Ed Harlow; Randolph S Watnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

8.  The regulation of M1 muscarinic acetylcholine receptor desensitization by synaptic activity in cultured hippocampal neurons.

Authors:  Jonathon M Willets; Carl P Nelson; Stefan R Nahorski; R A John Challiss
Journal:  J Neurochem       Date:  2007-10-01       Impact factor: 5.372

9.  Endothelin signalling in arterial smooth muscle is tightly regulated by G protein-coupled receptor kinase 2.

Authors:  Gavin E Morris; Carl P Nelson; Nicholas B Standen; R A John Challiss; Jonathon M Willets
Journal:  Cardiovasc Res       Date:  2009-09-11       Impact factor: 10.787

Review 10.  Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation.

Authors:  Mark E Obrenovich; Ludis A Morales; Celia J Cobb; Justin C Shenk; Gina M Méndez; Kathryn Fischbach; Mark A Smith; Eldar K Qasimov; George Perry; Gjumrakch Aliev
Journal:  J Cell Mol Med       Date:  2008-10-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.